A smart pill to track IBD
The ingestible device combines engineered bacteria with low-power electronics to monitor gut inflammation in real time.
Source: technologyreview.com
📰 Timothy Lu News
Timothy Lu News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Timothy Lu. Real-time updates on events, politics, business and more.
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H...
Timothy Lu Drug Administration Exchange Commission Securities Exchange Senti Biosciences Inc Gene Circuit
Source: marketscreener.com
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – –...
United States Kanya Rajangam Timothy Lu Ron Moldaver Head Of Research Development Exchange Commission
Source: marketscreener.com
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milestones and royalties – SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circ...
Source: yahoo.com
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary Gene Circuit platform – SOUTH SAN...
United States San Diego Timothy Lu Society For Immunotherapy Of Cancer Exchange Commission Securities Exchange
Source: marketscreener.com
Senti Bio Announces Multiple Data Presentations at the
– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary...
San Diego United States Timothy Lu Senti Biosciences Inc Securities Exchange Society For Immunotherapy Of Cancer
Source: globenewswire.com
Smart Pill Uses Luminescent Bacteria To Diagnose Gut Problems
Researchers from MIT, Boston University, the University of Chicago, Analog Devices, and Brigham and Women’s Hospital have developed a tiny...
Source: ubergizmo.com
Smart pill can track key biological markers in real-time
A new smart pill the size of a blueberry could be a game changer in the diagnosis and treatment of bowel diseases.
Source: mit.edu
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies – – Transaction... -Today at 08:36 am- MarketScreener
Source: marketscreener.com
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
20.05.2023 - Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophagesSOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) - Senti Biosciences, Inc. (Nasdaq: SNTI) ... Seite 1
Source: wallstreet-online.de